Literature DB >> 28812240

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified?

V López-López1, P A Cascales-Campos2, E Gil1, J Arevalo3, A Gonzalez1, J Gil1, F C Muñoz-Casares4, J T Melero5, P Barrios6, R Morales7, I Ramos6, G Ortega8, B Camps9, L González-Bayón10, P Bretcha-Boix11, J Farré-Alegre11, S González-Moreno12, P Parrilla1.   

Abstract

BACKGROUND: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei and appendix tumours are widespread in the world. It is unclear what should be the attitude in elderly patients.
METHODS: This retrospective multicenter study collected the database from ten Spanish centers from Spanish Group of Peritoneal Cancer Surgery. The study period was between November 2002 and March 2014. Seventeen patients with age greater than or equal to 75 years with peritoneal carcinomatosis from pseudomyxoma peritonei and appendix tumours met the selection criteria for the study. Outcomes in terms of morbidity and mortality such as disease-free and overall survival were analyzed.
RESULTS: Median PCI was 16 (range 6-39). Ten postoperative adverse events were detected in nine patients (44.4%). 28% were grade I-II and 17% were grade III-IV. Disease-free survival at 1 and 3 years was 67 and 44%, respectively. Overall survival at 1 and 3 years was 100 and 88%, respectively. Only cytoreduction was related to worst disease free survival after univariate (p = 0.007) and multivariate (OR 11.639, 95% CI 1.24-109.74, p = 0.03) analyses. Cytoreduction was related to the worst overall survival after univariate analysis (p = 0.046).
CONCLUSION: Cytoreductive surgery and HIPEC for pseudomyxoma peritonei and appendix tumours in elderly patients it is a procedure with feasible postoperative morbi-mortality and survival outcomes. TRIAL REGISTRATION: researchregistry1587 (retrospectively registered).

Entities:  

Keywords:  Appendix; Elderly; HIPEC; Morbidity; Pseudomyxoma peritonei; Survival

Mesh:

Year:  2017        PMID: 28812240     DOI: 10.1007/s12094-017-1728-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  26 in total

1.  Recommendations in the management of epithelial appendiceal neoplasms and peritoneal dissemination from mucinous tumours (pseudomyxoma peritonei).

Authors:  P Barrios; F Losa; S Gonzalez-Moreno; A Rojo; A Gómez-Portilla; P Bretcha-Boix; I Ramos; J Torres-Melero; R Salazar; M Benavides; T Massuti; E Aranda
Journal:  Clin Transl Oncol       Date:  2015-10-21       Impact factor: 3.405

2.  Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy.

Authors:  P H Sugarbaker; D Chang
Journal:  Ann Surg Oncol       Date:  1999-12       Impact factor: 5.344

3.  Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in elderly patients.

Authors:  Antonio Macrì; Edoardo Saladino; Giuseppe Trimarchi; Vincenzo Bartolo; Maurizio Rossitto; Antonio Cannaò; Antongiacomo Rizzo; Ciro Famulari
Journal:  In Vivo       Date:  2011 Jul-Aug       Impact factor: 2.155

4.  Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy.

Authors:  Thomas J Miner; Jinru Shia; David P Jaques; David S Klimstra; Murray F Brennan; Daniel G Coit
Journal:  Ann Surg       Date:  2005-02       Impact factor: 12.969

5.  Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei.

Authors:  S Alves; F Mohamed; G Yadegarfar; H Youssef; B J Moran
Journal:  Eur J Surg Oncol       Date:  2010-09-22       Impact factor: 4.424

Review 6.  Outcomes for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the elderly.

Authors:  Parissa Tabrizian; Ghalib Jibara; Brian Shrager; Bernardo Franssen; Ming-Jim Yang; Umut Sarpel; Spiros Hiotis; Daniel Labow
Journal:  Surg Oncol       Date:  2013-07-01       Impact factor: 3.279

7.  Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei.

Authors:  Z Güner; U Schmidt; M H Dahlke; H J Schlitt; J Klempnauer; P Piso
Journal:  Int J Colorectal Dis       Date:  2004-10-16       Impact factor: 2.571

8.  Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review.

Authors:  Robert F Bradley; John H Stewart; Gregory B Russell; Edward A Levine; Kim R Geisinger
Journal:  Am J Surg Pathol       Date:  2006-05       Impact factor: 6.394

9.  Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin.

Authors:  Haney Youssef; Christopher Newman; Kandiah Chandrakumaran; Faheez Mohamed; Tom D Cecil; Brendan J Moran
Journal:  Dis Colon Rectum       Date:  2011-03       Impact factor: 4.585

10.  Pancreatic or liver resection for malignancy is safe and effective for the elderly.

Authors:  Y Fong; L H Blumgart; J G Fortner; M F Brennan
Journal:  Ann Surg       Date:  1995-10       Impact factor: 12.969

View more
  1 in total

Review 1.  Efficacy and safety in the use of intraperitoneal hyperthermia chemotherapy and peritoneal cytoreductive surgery for pseudomyxoma peritonei from appendiceal neoplasm: A systematic review.

Authors:  Idevaldo Floriano; Antônio Silvinato; João C Reis; Claudia Cafalli; Wanderley Marques Bernardo
Journal:  Clinics (Sao Paulo)       Date:  2022-05-13       Impact factor: 2.898

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.